Dyslipidemias Clinical Trial
Official title:
Diets for Dyslipidemia in the Metabolic Syndrome
The metabolic syndrome consists of five concurrent conditions which increase risk of heart disease, stroke, and diabetes. Persons with the metabolic syndrome usually have high triglyceride and low HDL levels and are overweight. Low fat, high carbohydrate diets may not provide the same cholesterol-lowering benefits to obese individuals as they do to non-obese individuals. The purpose of this study is to compare the effects of a low fat, high carbohydrate diet versus a moderate fat, moderate carbohydrate diet on the heart, blood vessels, and cholesterol levels in individuals with metabolic syndrome.
The Metabolic Syndrome is characterized by elevated insulin levels, excess body fat in the
waist, and elevated levels of glucose and blood pressure, and dyslipidemia. Dyslipidemia in
the Metabolic Syndrome is characterized by high levels of triglycerides, low levels of HDL
cholesterol, and above average LDL and non-HDL cholesterol. Individuals with elevated LDL
cholesterol have traditionally been advised to follow a low fat, high carbohydrate diet.
However, research has shown that this diet does not adequately regulate cholesterol levels in
individuals with dyslipidemia. A diet consisting of more moderate amounts of fats and
carbohydrates may be more beneficial for individuals with the dyslipidemia of the metabolic
syndrome. The purpose of this study is to compare the effects of a diet moderate in fat and
carbohydrate versus a low fat, high carbohydrate diet on the cholesterol levels, inflammatory
factors and vascular response in individuals with metabolic syndrome.
During the initial screening period, participants follow an American Heart Association (AHA)
Step 1 diet and cholesterol levels are tested for eligibility under the criteria of the
Metabolic Syndrome. Before being randomized, eligible participants have a frequently sampled
intravenous glucose tolerance test (FSIVGTT), an abdominal CT scan to measure fat content in
two locations and two brachial artery reactivity tests. The FSIVGTT provides information
about whether participants are insulin sensitive or insulin resistant. The CT scan measures
the fat content in the abdomen and the liver. The brachial artery reactivity tests measure
blood flow through the brachial artery in the arm.
This 7-month study consists of two 1-month feeding periods, a rest month between the two
feeding periods and a 4-month follow-up diet in a free-living setting. In Month 1,
participants are randomly assigned to follow either a moderate fat, moderate carbohydrate
diet or a low fat, high carbohydrate diet. Participants receive prepared food at study visits
twice a week. Weight and vital signs are measured at each study visit, and blood is collected
at baseline, and Weeks 3-1/2 and 4. A brachial artery reactivity test, using an ultrasound to
measure artery size and blood flow in the arm, is performed twice in Week 4. In the Month 2
rest period, participants follow an AHA Step 1 diet at home. In Month 3, participants switch
to the other diet and all study procedures and evaluations are repeated as in Month 1. During
the following Months 4 through 7, participants continue following the second assigned diet,
but are responsible for preparing their own food. They meet with a dietician once a week for
1 month to learn how to prepare meals at home. During this 4-month period, blood collection,
vital sign measurements, and review of medical history and diet continue at monthly visits.
At the end of Month 7, participants again undergo two brachial artery reactivity tests.
As of October, 2010, 148 were screened with 71 eligible to be randomized. Seven discontinued
prior to completion and 64 completed the 7 month study. The intervention is complete and
analyses are ongoing.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Completed |
NCT04894318 -
The Effect Of Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Turkısh Dyslipidemic Patients
|
N/A | |
Completed |
NCT04862962 -
Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
|
||
Completed |
NCT04052594 -
A Study of LY3475766 in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT04270084 -
Metabolic Optimization Through Diet/Lifestyle Improvements For Youth
|
N/A | |
Completed |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
Completed |
NCT04516291 -
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
|
Phase 2 | |
Completed |
NCT03170752 -
Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A | |
Completed |
NCT04186780 -
Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study
|
N/A | |
Not yet recruiting |
NCT03674333 -
Effect of Adding Folic Acid on Lipid Parameters in Population With Dyslipidemias
|
N/A | |
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A | |
Terminated |
NCT01697735 -
The Therapeutic Effects of Statins and Berberine on the Hyperlipemia
|
Phase 4 | |
Completed |
NCT00455325 -
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
|
Phase 2 | |
Completed |
NCT00644709 -
A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)
|
Phase 4 | |
Recruiting |
NCT05624658 -
Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS
|
N/A | |
Recruiting |
NCT03988101 -
Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event
|
Phase 4 | |
Recruiting |
NCT06024291 -
Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial
|
N/A | |
Completed |
NCT01218204 -
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
|
Phase 2 | |
Completed |
NCT04079530 -
A Clinical Pharmacology Study of K-877 Controlled Release Tablet
|
Phase 2 |